Sichuan Biokin Pharmaceutical Co., Ltd. (688506.SH) has announced that it recently received formal approval from the National Medical Products Administration (NMPA) for the clinical trial of its self-developed innovative drug, BL-ARC002 injection. According to the announcement, BL-ARC002 utilizes antibody-mediated precision targeting delivery technology combined with the potent tumor-killing capability of radionuclides. Compared to traditional radionuclide conjugate drugs, it demonstrates stronger target specificity, higher tumor enrichment, and is expected to exhibit improved resistance to drug resistance.